Table 3.

Effect of Randomized Vitamin E Assignment on Visually Significant Age-related Macular Degeneration by Subgroups.

	No. of AMD/Total
	Vitamin E	Placebo	RR*	95% CI	P-value	P(test of interaction)
Age, y						0.09
45–54	9/11,949	20/11,958	0.45	0.21–1.00	0.049
55–64	38/5,807	40/5,800	0.95	0.61–1.48	0.81
≥65	70/1,941	68/1,966	1.05	0.75–1.46	0.78
Smoke Cigarettes						0.89
Current	19/2,569	22/2,622	0.91	0.49–1.68	0.76
Past/Never	97/17,110	106/17,085	0.92	0.70–1.22	0.57
Alcohol Use						0.99
<1/wk	74/11,517	81/11,431	0.91	0.66–1.24	0.55
≥1/wk	43/8,173	47/8,290	0.96	0.64–1.46	0.85
Body-mass index						0.13
<25.0	64/9,763	56/9,866	1.18	0.82–1.69	0.37
25.0–29.9	30/5,999	38/5,953	0.77	0.48–1.24	0.28
≥30.0	23/3,519	30/3,520	0.78	0.45–1.34	0.37
Hypertension						0.40
Yes	51/4,995	50/5,130	1.05	0.71–1.54	0.83
No	66/14,700	78/14,587	0.84	0.61–1.17	0.31
Hyperlipidemia						0.20
Yes	49/5,736	44/5,819	1.17	0.78–1.76	0.45
No	68/13,955	84/13,895	0.81	0.59–1.11	0.18
Diabetes						0.35
Yes	3/497	6/494	0.45	0.11–1.80	0.26
No	114/19,191	122/19,215	0.95	0.73–1.22	0.67
Menopausal status and use of HT						0.38
Premenopausal	4/5,431	6/5,490	0.70	0.20–2.50	0.59
Uncertain	4/3,532	11/3,556	0.37	0.12–1.15	0.09
Postmenopausal and current HT	39/5,907	38/5,892	1.05	0.67–1.64	0.83
Postmenopausal and no HT	70/4,777	73/4,736	0.96	0.69–1.33	0.80
Parental history of MI before 60 yrs of age						0.82
Yes	10/2,301	12/2,284	0.83	0.36–1.92	0.66
No	90/15,384	104/15,455	0.88	0.66–1.16	0.35
Multivitamin Use						0.52
Current	43/7,185	53/7,080	0.81	0.54–1.21	0.30
Past/Never	73/12,233	75/12,369	0.99	0.72–1.37	0.95
Eye exam in past 2 yrs						0.65
Yes	98/16,262	111/16,321	0.90	0.69–1.18	0.46
No	19/3,431	17/3,400	1.07	0.55–2.05	0.85

Abbreviations: AMD, age-related macular degeneration; CI, confidence interval; HT, hormone therapy; MI, myocardial infarction.

^*Adjusted for age and aspirin and beta carotene treatment assignment